Scarica l'app Stockscreener
0.715
0.11%
-0.0008
Dopo l'orario di chiusura:
.73
0.015
+2.10%
Precedente Chiudi:
$0.7158
Aprire:
$0.74
Volume 24 ore:
95,864
Relative Volume:
0.15
Capitalizzazione di mercato:
$2.41M
Reddito:
-
Utile/perdita netta:
$-7.90M
Rapporto P/E:
-0.00385
EPS:
-185.9263
Flusso di cassa netto:
$-6.29M
1 W Prestazione:
-10.96%
1M Prestazione:
-61.35%
6M Prestazione:
-93.38%
1 anno Prestazione:
-99.82%
Intervallo 1D:
$0.7055
$0.74
Intervallo di 1 settimana:
$0.7055
$0.8399
Portata 52W:
$0.7055
$480.00
Clearmind Medicine Inc Stock (CMND) Company Profile
Nome
Clearmind Medicine Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare CMND vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.715 | 2.70M | 0 | -7.90M | -6.29M | -185.93 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Clearmind Medicine Inc Borsa (CMND) Ultime notizie
Clearmind Medicine Inc Share PriceCMND, RNS News, Articles, Quotes, & Charts (NASDAQ:CMND) - Proactive financial news
Clearmind Medicine reports three published US patent applications - Mugglehead Investment Magazine
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration With Clearmind Covering LSD, Ketamine and Ibogaine Combinations - Yahoo Finance
Three patent applications pair LSD, ketamine and ibogaine with a proprietary compound. - Stock Titan
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations - thenewswire.com
NeuroThera Labs Expands U.S. Patent Portfolio With LSD, Ketamine and Ibogaine Combinations via Clearmind Collaboration - kalkine.ca
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations - The Manila Times
Clearmind Medicine Announces U.S. Publication of Patent Applications Covering LSD, Ketamine and Ibogaine Combinations with N-Acylethanolamines - Quiver Quantitative
Clearmind testifies at FDA hearing on psychedelic therapies - Investing.com
Clearmind testifies at FDA hearing on psychedelic therapies By Investing.com - Investing.com Canada
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C. - The Manila Times
About 1,800 people joined the FDA’s psychedelic hearing. Clearmind spoke on patient access. - Stock Titan
Why Did CMND Stock Jump 40% Today? - Stocktwits
Clearmind enrolls first AUD patients in CMND-100 trial - grafa.com
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial - The Manila Times
Clearmind enrolls first AUD patients in CMND-100 clinical trial By Investing.com - Investing.com UK
Two patients become the first to receive Clearmind's potential treatment for alcohol use disorder. - Stock Titan
Clearmind enrolls first AUD patients in CMND-100 clinical trial - Investing.com
Proposed Nasdaq threshold could threaten Clearmind (NASDAQ: CMND) listing - Stock Titan
Clearmind Medicine(CMND) Stock Options Chain | Quotes & News - Moomoo
Charging Robotics Inc. Sells Majority Stake in Charging Israel to Clearmind Medicine for $2.5M (OTC: CHEV) - kalkinemedia.com
Clearmind gets Yale IRB approval for AUD trial enrollment By Investing.com - Investing.com India
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results - The Manila Times
All 24 trial participants completed treatment with no serious adverse events. Yale can now recruit. - stocktitan.net
Clearmind to acquire 51% stake in EV charging firm for $2.5M By Investing.com - Investing.com Australia
Clearmind Medicine to Acquire Majority Stake in Charging Robotics for $2.5 Million - marketscreener.com
CMND Stock Slides As Clearmind Medicine Tightens Cash Belt - StocksToTrade
Clearmind Tumbles on Buying into Charging Robotics - Baystreet.ca
Clearmind Medicine Agrees to Acquire 51% Stake in Charging Robotics for $2.5 Million - Yahoo Finance
Clearmind Medicine Stock Slides Friday: What's Happening? - Benzinga
CMND Stock Slides As Traders Eye Key Support Levels - timothysykes.com
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis - The Manila Times
Clearmind Medicine CMND-100 Advances As Psychedelic Pipeline Builds - StocksToTrade
Clearmind to acquire 51% stake in EV charging firm for $2.5M - Investing.com UK
Clearmind Medicine Inc. (CMND) moves into EV wireless charging with a controlling deal - Stock Titan
Clearmind Medicine ลงนามในข้อตกลงขั้นสุดท้ายเพื่อเข้าซื้อหุ้น 51% ในบริษัทระบบชาร์จไร้สายสำหรับระบบจอดรถอัตโนมัติและรถแท็กซี่ไร้คนขับ (Robotaxis) - Moomoo
Debt-for-share swap at $1 sets new floor at Clearmind (CMND) - Stock Titan
Clearmind Medicine Inc. (CMND) Stock: Jumps Nearly 10% as Phase IIa AUD Trial Begins - Blockonomi
Clearmind starts Phase IIa AUD trial of CMND-100 - Stock Titan
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled - The Manila Times
Clearmind Medicine Announces Initiation of Phase IIa Trial for CMND-100 in Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine (CMND) Slips 2.76% to $1.76, Holds Above Key Support at $1.67ALMA Signal - careplusvn.com
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation - The Manila Times
NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation - NewMediaWire
SciSparc: NeuroThera-Clearmind Collaboration Advances - GlobeNewswire
Clearmind (CMND) Market: Adds 0.87% to Close at $1.74; Chart Watch: Support at $1.65 and Resistance at $1.83 Frame the Range in the Latest SessionVolume Rate Change - vinanet.vn
Clearmind Medicine Company Profile & Introduction - Moomoo
Clearmind Medicine (CMND) Holds Near $1.86 as Biotech Stock Consolidates Within Key RangeFibonacci Extension - vinanet.vn
Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial - Benzinga
Clearmind Medicine Receives DSMB Approval to Advance CMND-100 Clinical Trial in Patients With Alcohol Use Disorder - Quiver Quantitative
Clearmind's CMND-100 Will Be Tested in People With Alcohol Use Disorder - Stock Titan
Clearmind Medicine Inc Azioni (CMND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Clearmind Medicine Inc Azioni (CMND) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 10% Owner |
Jun 15 '26 |
Sale |
3.32 |
3,183 |
10,568 |
103,492 |
| HRT FINANCIAL LP | 10% Owner |
Jun 12 '26 |
Sale |
3.36 |
2,102 |
7,063 |
106,675 |
| HRT FINANCIAL LP | 10% Owner |
Jun 10 '26 |
Buy |
0.15 |
2,159,052 |
330,335 |
2,063,266 |
| HRT FINANCIAL LP | 10% Owner |
Jun 11 '26 |
Sale |
0.12 |
225,191 |
27,698 |
1,838,075 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):